Ab&B gains as human rabies vaccine commences Phase III clinical trials

Ab&B Bio Tech JS

09/12/2025 03:26

** Ab&B Bio-Tech 2627.HK rises 1.7% to HK$40.88; set for biggest one-day pct gain since November 25

** China-based vaccines developer initiates Phase III clinical trials of its Lyophilized Human Rabies Vaccine (Human Diploid Cell)

** Co says rabies vaccine candidate demonstrated promising safety profile in its completed Phase I clinical trial in October 2024

** Since debut on August 11, stock surges 213.6%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))